GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Total Current Liabilities

Psyence Biomedical (Psyence Biomedical) Total Current Liabilities : $1.77 Mil (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Psyence Biomedical's total current liabilities for the quarter that ended in Mar. 2023 was $1.77

Psyence Biomedical Total Current Liabilities Historical Data

The historical data trend for Psyence Biomedical's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Total Current Liabilities Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Total Current Liabilities
0.10 0.13 1.77

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Total Current Liabilities 0.10 0.13 1.77

Psyence Biomedical Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Psyence Biomedical's Total Current Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.771+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.77

Psyence Biomedical's Total Current Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.771+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Psyence Biomedical Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Total Current Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Website
https://www.psyence.com
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024